Analysed ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) News Sources
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
17-03-2026
yahoo.com
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
17-03-2026
yahoo.com
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest
05-04-2026
yahoo.com
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
06-04-2026
yahoo.com
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
15-04-2026
yahoo.com
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07-05-2026
yahoo.com
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
10-05-2026
yahoo.com
What is the current price of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The current price of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is $27.47.
ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) since the previous trading day is $-0.47.
ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) since the previous trading day is -1.6822%.
What is the most recent average sentiment score for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The most recent average sentiment score for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The most recent sentiment for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is .
SEC-8K** Filing Available For ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.